Show simple item record

dc.contributor.authorByth, Lachlan A
dc.contributor.authorByth, Jenny
dc.date.accessioned2021-06-02T23:25:34Z
dc.date.available2021-06-02T23:25:34Z
dc.date.issued2021
dc.identifier.issn0004-8380en_US
dc.identifier.doi10.1111/ajd.13601en_US
dc.identifier.urihttp://hdl.handle.net/10072/404882
dc.description.abstractBackground/Objectives: Disseminated superficial actinic porokeratosis (DSAP) is a porokeratosis variant that is cosmetically disfiguring and may be associated with squamous cell carcinoma. It is an autosomal dominant condition caused by germline mutations in mevalonate pathway genes involved in cholesterol synthesis. Lesions are precipitated by ultraviolet radiation-induced second-hit mutations. Modulation of this pathway by topical simvastatin–cholesterol may lead to improvement. Methods: This open-label, split-body clinical trial was carried out in 2020 at a metropolitan dermatology clinic. Eight patients contributing 13 limb pairs were recruited. Limbs within each pair were randomly allocated to 2% simvastatin/2% cholesterol cream applied twice daily or bland emollients. Lesion number, erythema, scale and patient-reported disease activity were measured at baseline and 6 weeks. Data were analysed using Bayesian ordinal logistic regression. Odds ratios compare the odds of a higher score at 6 weeks in treated limbs with the odds in controls. Values less than one indicate improvement. Results: Patients had a median age of 65 years (interquartile range [IQR] 58 to 69 years). The median baseline DLQI was 5 (range 2–21). Odds ratios were 0.12 (95% credible interval [CI] 0.01 to 0.72) for lesion number, 0.25 (95% CI 0.05 to 0.79) for erythema score, 0.18 (95% CI 0.03 to 0.64) for scale score and 0.33 (95% CI 0.09 to 0.89) for patient-reported disease activity. Conclusions: Topical simvastatin–cholesterol cream improved lesion number, erythema and scale on treated limbs compared with controls. Patient-reported disease activity also improved. These findings warrant confirmation in blinded, vehicle-controlled trials.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.relation.ispartofjournalAustralasian Journal of Dermatologyen_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchPaediatrics and Reproductive Medicineen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.fieldofresearchcode1114en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsDermatologyen_US
dc.subject.keywordscholesterolen_US
dc.subject.keywordsneoplasmen_US
dc.titleTopical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: An open-label, split-body clinical trialen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationByth, LA; Byth, J, Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: An open-label, split-body clinical trial, Australasian Journal of Dermatology, 2021en_US
dcterms.dateAccepted2021-03-10
dc.date.updated2021-06-01T22:38:03Z
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.en_US
gro.hasfulltextNo Full Text
gro.griffith.authorByth, Lachlan A.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record